NASDAQ:SNDX Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis $18.67 -1.17 (-5.90%) As of 03:46 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Syndax Pharmaceuticals Stock (NASDAQ:SNDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Syndax Pharmaceuticals alerts:Sign Up Key Stats Today's Range$18.40▼$19.6950-Day Range$19.05▼$24.8452-Week Range$12.99▼$25.59Volume1.15 million shsAverage Volume1.57 million shsMarket Capitalization$1.65 billionP/E RatioN/ADividend YieldN/APrice Target$42.30Consensus RatingModerate Buy Company Overview Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology. The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications. Entinostat is currently in Phase 3 development in combination with pembrolizumab for patients with hormone receptor-positive, HER2-negative advanced breast cancer. Syndax’s pipeline also includes SNDX-5613 (revumenib), a menin inhibitor targeting acute leukemias harboring MLL rearrangements or NPM1 mutations, which is advancing through Phase 2 clinical trials. In addition to these core programs, Syndax is exploring combination strategies to maximize clinical benefit and address resistance mechanisms. The company was founded in 2002 and has cultivated collaborations with leading academic institutions and industry partners to accelerate development and broaden the reach of its therapies. Syndax operates primarily in the United States but plans to expand its global footprint through strategic partnerships and licensing agreements. Under the leadership of President and Chief Executive Officer Daniel A. Swisher and Chief Financial Officer Wolfgang R. Grosse, Syndax continues to build a pipeline designed to deliver meaningful improvements in outcomes for cancer patients worldwide.AI Generated. May Contain Errors. Read More Syndax Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreSNDX MarketRank™: Syndax Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat, and ranked 392nd out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingSyndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialSyndax Pharmaceuticals has a consensus price target of $42.30, representing about 129.1% upside from its current price of $18.46.Amount of Analyst CoverageSyndax Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Syndax Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($2.01) to ($0.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syndax Pharmaceuticals is -7.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syndax Pharmaceuticals is -7.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyndax Pharmaceuticals has a P/B Ratio of 24.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Syndax Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted27.15% of the float of Syndax Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSyndax Pharmaceuticals has a short interest ratio ("days to cover") of 15.03, which indicates bearish sentiment.Change versus previous monthShort interest in Syndax Pharmaceuticals has recently increased by 1.05%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSyndax Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyndax Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.08 News SentimentSyndax Pharmaceuticals has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Syndax Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest8 people have searched for SNDX on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.MarketBeat Follows3 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Syndax Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,968,413.00 in company stock.Percentage Held by Insiders4.80% of the stock of Syndax Pharmaceuticals is held by insiders.Percentage Held by InstitutionsSyndax Pharmaceuticals has minimal institutional ownership at this time.Read more about Syndax Pharmaceuticals' insider trading history. Receive SNDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNDX Stock News HeadlinesSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)September 4, 2026 | globenewswire.comSyndax Announces Participation in September Investor ConferencesSeptember 1, 2026 | globenewswire.comWashington Is Broke—Could YOUR Savings Be Next?The Department of Justice recently argued in court that cash is not legally property, raising new questions for savers as federal debt continues to climb. Your IRA, 401k, and bank accounts are not hidden from view, prompting some Americans to look for ways to keep more control over their own wealth. A free information kit outlines three strategies people are considering to help shield their savings from future policy changes.September 10 at 1:00 AM | Priority Gold (Ad)Syndax (SNDX) Q2 2026 Earnings Call TranscriptAugust 11, 2026 | finance.yahoo.comHow Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) InvestorsAugust 8, 2026 | finance.yahoo.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)August 5, 2026 | globenewswire.comSyndax Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call PresentationAugust 5, 2026 | seekingalpha.comSyndax Pharmaceuticals (SNDX) Q2 2026August 5, 2026 | 247wallst.comSee More Headlines SNDX Stock Analysis - Frequently Asked Questions How have SNDX shares performed this year? Syndax Pharmaceuticals' stock was trading at $21.01 at the beginning of 2026. Since then, SNDX shares have decreased by 12.1% and is now trading at $18.46. How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) released its earnings results on Tuesday, August, 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.10. Syndax Pharmaceuticals's revenue for the quarter was up 91.8% on a year-over-year basis. Read the conference call transcript. When did Syndax Pharmaceuticals IPO? Syndax Pharmaceuticals (SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. Who are Syndax Pharmaceuticals' major shareholders? Syndax Pharmaceuticals' top institutional shareholders include BlackRock Inc. (10.18%), Bank of America Corp DE (4.57%), California State Teachers Retirement System (2.31%) and Elmind Capital LP (2.09%). Insiders that own company stock include Michael A Metzger, Dennis Podlesak, Keith A Goldan, Neil Gallagher and Nicholas AJ Botwood. View institutional ownership trends. How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Syndax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Syndax Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and ServiceNow (NOW). Company Calendar Last Earnings8/04/2026Today9/10/2026Citigroup’s Biopharma Back to School Summit 20269/10/2026H.C. Wainwright 28th Annual Global Investment Conference9/15/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 SNDX's financial health is in the Green zone, according to TradeSmith. SNDX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SNDX CIK1395937 Webwww.syndax.com Phone(781) 419-1400Fax781-419-1420Employees110Year Founded2005Price Target and Rating Average Price Target for Syndax Pharmaceuticals$42.30 High Price Target$57.00 Low Price Target$33.00 Potential Upside/Downside+126.0%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$285.42 million Net Margins-87.52% Pretax Margin-87.52% Return on Equity-372.94% Return on Assets-39.11% Debt Debt-to-Equity Ratio38.95 Current Ratio6.77 Quick Ratio6.44 Sales & Book Value Annual Sales$172.35 million Price / Sales9.62 Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book25.30Miscellaneous Outstanding Shares88,610,000Free Float84,357,000Market Cap$1.66 billion OptionableOptionable Beta0.37 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:SNDX) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our PartnersGold Explorer Sits Between Barrick’s Nevada GiantsBarrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...Wall Street Logic | SponsoredShocking AI prediction from the “Billionaire Whisperer"Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...Cedar Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
